ABSTRACT
One hundred and twenty nine nulliparous requesting first trimester induced abortion between 7 and 12 weeks of amenorrhea (SA) were included in the study to evaluate the effectiveness and the side effects of misoprostol in the cervical ripening before aspiration. Three randomized groups of 43 patients received misoprostol 12 hours before induced abortion: group A received 200 mug inserted vaginally; group B received 400 mu g inserted vaginally and group C received 400 mu g orally. Cervical dilatation after treatment and maximal dilatation realized with Hegar dilatator were significantly higher in group B. The rate of partial abortion is significantly higher in group B. Tolerance is good in the three groups. No significant difference between the three groups related digestive disorders, pelvic pain and hyperthermia were noted. On the other hand the rate of metrorrhagia and hemorrhages more important than menstruation is higher in group B. Misoprostol 400 mu g inserted vaginally 12 hours before induced abortion in nulliparous women seem to be an effective, safe, practical and cheap method for cervical ripening before aspiration.
Subject(s)
Abortifacient Agents, Nonsteroidal , Abortion, Induced/methods , Misoprostol , Premedication/methods , Administration, Intravaginal , Administration, Oral , Adult , Female , Humans , Parity , Pregnancy , Pregnancy Trimester, First , Prospective Studies , Time FactorsABSTRACT
OBJECTIVE: To assess the effectiveness and side effects of misoprostol versus suprostone in cervix preparation before aspiration abortion in the nullipara. METHODS: Ninety nulliparous women requesting medical abortion with gestations varying from 7 to 12 weeks were included in a prospective randomized study after informed consent. Women with contraindications for prostaglandins and those consulting before 7 weeks gestation were excluded from the study. The women were assigned to 30 groups randomly: women in group A were given 500 micrograms sulprostone in 250 saline solution infused at a rate of 100 micrograms/h 12 hours before the abortion; women in groupe B were given 400 micrograms misoprostol per os 3 hours before abortion; and women in groupe C were given 400 micrograms misoprostol per os 12 hours before abortion. RESULTS: The three groups were not different for age, parity or gestation, gestational age at abortion or type of anaesthesia. Dilatation of the cervix after treatment was identical in groups A and C (8.60 +/- 1.3 vs 8.20 +/- 1.3; NS) but was greater in group A than in group B (8.60 +/- 1.3 vs 7.23 +/- 2.2; p = 0.02). Maximal dilatation was the same in the three groups (9.50 +/- 0.8, 9.10 +/- 1.3, 9.17 +/- 0.8 respectively). Rate of partial expulsion was higher in groups A and C (23 and 6%) compared with group B (0%). Tolerance was much better with misprosol than with sulprostone: 43% digestive disorders in group A versus 15% in groupe B and C (p = 0.003); 80% pelvic pain with sulprostone versus 53% with misoprostol (p = 0.01); 70% metrorrhagie with sulprostone versus 38% with misoprostol (p = 0.04) and 36% with more bleeding than cycles in the sulprostone subjects versus 12% in the misoprostol subjects (p = 0.005). CONCLUSION: Misoprostol at a dose of 400 micrograms per os 12 hours before abortion in the nullipara is an interesting alternative to sulprostone. It is equally effective for cervix dilatation, tolerance is much better and cost is lower.
Subject(s)
Abortifacient Agents, Nonsteroidal/therapeutic use , Abortion, Induced/methods , Dinoprostone/analogs & derivatives , Misoprostol/therapeutic use , Premedication/methods , Vacuum Curettage/methods , Administration, Oral , Adult , Cervix Uteri/drug effects , Dinoprostone/therapeutic use , Female , Humans , Infusions, Intravenous , Parity , Pregnancy , Prospective StudiesABSTRACT
Hybridoma cells which secrete colorectal carcinoma-specific antibodies have been produced and used to study the antigenic structure of these tumor cells. Nineteen antibodies have been studied in detail, and 15 of these are colorectal carcinoma specific. Only two antibodies reactive with carcinoembryonic antigen (CEA) have been discovered and five other antibodies that react with distinct epitopes on the cell surface have been defined. Several antigens with distinct molecular characteristics have been shown to exist by use of hybridoma antibodies. Six hybridoma antibodies have been shown to mediate antibody-dependent cell-mediated cytotoxicity (ADCC).
